Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility

References

• Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654–2662. doi:10.1056/NEJMra1500587
   PubMed Web of Science ®Google Scholar
• Thorpy MJ. Narcolepsy, a Clinical Guide. 2nd ed. Switzerland: Springer International Publishing; 2015.
   Google Scholar
• Darien I. International Classification of Sleep Disorders. 3rd ed. American Academy of Sleep Medicine;2014.
   Google Scholar
• Longstreth WT, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30(1):13–26. doi:10.1093/sleep/30.1.13
   PubMed Web of Science ®Google Scholar
• Hale L, Guan S, Emanuele E. Narcolepsy: A Clinical Guide. 2nd ed. Switzerland: Springer International Publishing; 2015.
   Google Scholar
• Scheer D, Schwartz SW, Parr M, Zgibor J, Sanchez-Anguiano A, Rajaram L. Prevalence and incidence of narcolepsy in a US health care claims database, 2008-2010. Sleep. 2019;42.
   Web of Science ®Google Scholar
• Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002;25(2):197–202. doi:10.1093/sleep/25.2.197
   PubMed Web of Science ®Google Scholar
• Guilleminault C, Billiard M, Montplaisir J, Dement WC. Altered states of consciousness in disorders of daytime sleepiness. J Neurol Sci. 1975;26(3):377–393. doi:10.1016/0022-510X(75)90209-9
   PubMed Web of Science ®Google Scholar
• Scammell TE, Arrigoni E, Lipton JO. Neural circuitry of wakefulness and sleep. Neuron. 2017;93(4):747–765. doi:10.1016/j.neuron.2017.01.014
   PubMed Web of Science ®Google Scholar
• Mahoney CE, Cogswell A, Koralnik IJ, Scammell TE. The neurobiological basis of narcolepsy. Nat Rev Neurosci. 2019;20(2):83–93. doi:10.1038/s41583-018-0097-x
   PubMed Web of Science ®Google Scholar
• Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000;355(9197):39–40. doi:10.1016/S0140-6736(99)05582-8
   PubMed Web of Science ®Google Scholar
• Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007;8(3):171–181. doi:10.1038/nrn2092
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron. 2003;38(5):715–730. doi:10.1016/S0896-6273(03)00330-1
   PubMed Web of Science ®Google Scholar
• Willie JT, Renthal W, Chemelli RM, et al. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience. 2005;130(4):983–995. doi:10.1016/j.neuroscience.2004.10.005
   PubMed Web of Science ®Google Scholar
• Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999;98(3):365–376. doi:10.1016/S0092-8674(00)81965-0
   PubMed Web of Science ®Google Scholar
• Haas HL, Sergeeva OA, Selbach O. Histamine in the nervous system. Physiol Rev. 2008;88:1183–1241.
   PubMed Web of Science ®Google Scholar
• Schwartz JC. The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol. 2011;163(4):713–721. doi:10.1111/j.1476-5381.2011.01286.x
   PubMed Web of Science ®Google Scholar
• Ghamari N, Zarei O, Arias-Montaño JA, et al. Histamine H. Pharmacol Ther. 2019;200:69–84. doi:10.1016/j.pharmthera.2019.04.007
   PubMed Web of Science ®Google Scholar
• Schlicker E, Kathmann M. Role of the Histamine H. Handb Exp Pharmacol. 2017;241:277–299.
   PubMedGoogle Scholar
• Sundvik M, Panula P. Interactions of the orexin/hypocretin neurones and the histaminergic system. Acta Physiol (Oxf). 2015;213(2):321–333. doi:10.1111/apha.12432
   Web of Science ®Google Scholar
• Eriksson KS, Sergeeva O, Brown RE, Haas HL. Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci. 2001;21(23):9273–9279. doi:10.1523/JNEUROSCI.21-23-09273.2001
   PubMed Web of Science ®Google Scholar
• Kaslin J, Nystedt JM, Ostergård M, Peitsaro N, Panula P. The orexin/hypocretin system in zebrafish is connected to the aminergic and cholinergic systems. J Neurosci. 2004;24(11):2678–2689. doi:10.1523/JNEUROSCI.4908-03.2004
   Web of Science ®Google Scholar
• Sundvik M, Kudo H, Toivonen P, Rozov S, Chen YC, Panula P. The histaminergic system regulates wakefulness and orexin/hypocretin neuron development via histamine receptor H1 in zebrafish. FASEB J. 2011;25(12):4338–4347. doi:10.1096/fj.11-188268
   Web of Science ®Google Scholar
• Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435(1):6–25. doi:10.1002/cne.1190
   PubMed Web of Science ®Google Scholar
• Yamanaka A, Tsujino N, Funahashi H, et al. Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun. 2002;290(4):1237–1245. doi:10.1006/bbrc.2001.6318
   Web of Science ®Google Scholar
• Lin L, Wisor J, Shiba T, et al. Measurement of hypocretin/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background. Peptides. 2002;23(12):2203–2211. doi:10.1016/S0196-9781(02)00251-6
   Web of Science ®Google Scholar
• Nishino S, Sakurai E, Nevsimalova S, et al. Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep. 2009;32(2):175–180. doi:10.1093/sleep/32.2.175
   Web of Science ®Google Scholar
• Bassetti CL, Baumann CR, Dauvilliers Y, Croyal M, Robert P, Schwartz JC. Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin. J Sleep Res. 2010;19(4):620–623. doi:10.1111/j.1365-2869.2010.00819.x
   PubMed Web of Science ®Google Scholar
• Kanbayashi T, Kodama T, Kondo H, et al. CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep. 2009;32(2):181–187. doi:10.1093/sleep/32.2.181
   PubMed Web of Science ®Google Scholar
• Neikrug AB, Ong JC. Narcolepsy: A Clinical Guide. 2nd ed. Switzerland: Springer International Publishing; 2015.
   Google Scholar
• Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301(11):1148–1154. doi:10.1001/jama.2009.351
   PubMed Web of Science ®Google Scholar
• Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34(1):9–27. doi:10.1007/s40263-019-00689-1
   PubMed Web of Science ®Google Scholar
• Barateau L, Lopez R, Dauvilliers Y. Management of narcolepsy. Curr Treat Options Neurol. 2016;18(10):43. doi:10.1007/s11940-016-0429-y
   PubMed Web of Science ®Google Scholar
• de Biase S, Gigli GL, Valente M. Important decisions in choosing the pharmacotherapy for narcoleptics. Expert Opin Pharmacother. 2019;20(5):483–486. doi:10.1080/14656566.2018.1561861
   PubMed Web of Science ®Google Scholar
• Syed YY. Pitolisant: first global approval. Drugs. 2016;76(13):1313–1318. doi:10.1007/s40265-016-0620-1
   PubMed Web of Science ®Google Scholar
• Uguen M, Perrin D, Belliard S, et al. Preclinical evaluation of the abuse potential of Pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with Modafinil. Br J Pharmacol. 2013;169(3):632–644. doi:10.1111/bph.12149
   PubMed Web of Science ®Google Scholar
• Setnik B, McDonnell M, Mills C, et al.Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy. Sleep. 2019.
   PubMed Web of Science ®Google Scholar
• Wakix:Highlights of prescribing information. Plymouth Meeting, PA. 2020
   Google Scholar
• Riddy DM, Cook AE, Shackleford DM, et al. Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H(3) receptor antagonists. Neuropharmacology. 2019;144:244–255. doi:10.1016/j.neuropharm.2018.10.028
   PubMed Web of Science ®Google Scholar
• EMA. EMA. Wakix Assessment Report. 2015
   Google Scholar
• Lamb YN. Pitolisant: a review in narcolepsy with or without cataplexy. CNS Drugs. 2020;34(2):207–218. doi:10.1007/s40263-020-00703-x
   Web of Science ®Google Scholar
• Wakix. Summary of product characteristics. Bioprojet Pharma. 2016
   Google Scholar
• Emerson E. Newly approved narcolepsy product has a price tag exceeding 100K annually. Crumdale Partners. 2020.
   Google Scholar
• Bolin K, Niska P, Pirhonen L, Wasling P, Landtblom AM. The cost utility of pitolisant as narcolepsy treatment. Acta Neurol Scand. 2019.
   Web of Science ®Google Scholar
• Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis. 2008;30(1):74–83. doi:10.1016/j.nbd.2007.12.003
   PubMed Web of Science ®Google Scholar
• EMA. Wakix assessment. 2020. Available from: https://www.ema.europ. Accessed August 18, 2020.
   Google Scholar
• Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068–1075. doi:10.1016/S1474-4422(13)70225-4
   PubMed Web of Science ®Google Scholar
• Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200–207. doi:10.1016/S1474-4422(16)30333-7
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Arnulf I, Szakacs Z, et al. Long-term use of pitolisant to treat patients with narcolepsy: harmony III Study. Sleep. 2019:42.
   Google Scholar
• Solanges M. Pitolisant: Clinical Review. Rev of Safety. Data provided by the U.S. Food and Drug Administration. 2019;332. Available from: https://www.accessdata.fda.gov. Accessed August 18, 2020
   Google Scholar
• Scart-Grès C, Momah C, Roy M, Maski K, Piris S, RK B. Safety and tolerability of pitolisant in the treatment of adults. Sleep. 2019;42(Supplement_1):A244–5. doi:10.1093/sleep/zsz067.612
   Google Scholar
• Bauer E, Davis C, Patroneva A, Dayno J, Thorpy M. The safety and tolerability of pitolisant in the treatment of excessive daytime sleepiness and cataplexy in adult patients with narcolepsy: an open-label, expanded access program in the United States [abstract no. 0611]. sleep. 2019;42(suppl1):A243. doi:10.1093/sleep/zsz067.609
   Google Scholar
• Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M. The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the committee for medicinal products for human use. Sleep Med. 2017;33:125–129. doi:10.1016/j.sleep.2017.01.002
   PubMed Web of Science ®Google Scholar
• Kallweit U, Triller A. Effects of pitolisant on nighttime sleep [abstract no. 0613]. sleep. 2019;42(suppl1):A244. doi:10.1093/sleep/zsz067.611
   Google Scholar
• Huyts B, Brabant C, Tirelli E. Pitolisant and intravenous cocaine self-administration in mice. Eur J Pharmacol. 2019;851:63–68. doi:10.1016/j.ejphar.2019.02.019
   PubMed Web of Science ®Google Scholar
• Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep. 2018;41.
   Google Scholar
• Roth T, Dauvilliers Y, Guinta D, Alvarez-Horine S, Dynin E, Black J. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res. 2017;26(4):407–414. doi:10.1111/jsr.12468
   PubMed Web of Science ®Google Scholar